Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.
Overview
This section identifies the active ingredient and other related pharmaceutical products available in the Canadian market.
Wegovy® is a brand-name medication that utilizes semaglutide as its active pharmaceutical ingredient. In Canada, semaglutide is also marketed under the brand names Ozempic® (injectable) and Rybelsus® (oral tablet). Other medications in the same therapeutic class available to Canadians include Saxenda® (liraglutide) and Mounjaro® (tirzepatide). While these products share similar pharmaceutical properties, their concentrations and delivery methods vary.
This medication is available in Canada as liquid-filled pens in several distinct strengths for precise administration.
Wegovy® is supplied as a solution for injection in pre-filled, multi-dose FlexTouch® pens. In the Canadian pharmaceutical market, it is typically available in the following strengths:
- 0.25 mg
- 0.5 mg
- 1.0 mg
- 1.7 mg
- 2.4 mg
How Wegovy Works
Wegovy® mimics a natural hormone in the body to regulate various biological and metabolic processes.
At a biological level, Wegovy® acts as a GLP-1 (glucagon-like peptide-1) receptor agonist. It is designed to bind to and activate GLP-1 receptors throughout the body. This action mimics a natural hormone usually released after eating, which helps regulate the rate of stomach emptying and influences the brain's signals regarding fullness.
Dosage Instructions of Wegovy
Users follow a specific weekly schedule using pre-filled pens as directed by their healthcare provider.
Wegovy® is administered as a subcutaneous injection (under the skin) once every seven days. Common injection sites include the abdomen, thigh, or upper arm. It is important to rotate the injection site with each dose. The dosage is usually started at a lower level and increased gradually over several months following a specific "titration" schedule defined by a professional.
Storage Instructions
Keeping the medication at the correct temperature ensures it remains safe and effective for use. Unused Pens: Must be stored in a refrigerator between 2°C and 8°C. In-Use Pens: Can be kept at room temperature (up to 30°C) or in the refrigerator for up to 28 days. Protection: Do not freeze. Keep the pen cap on to protect the medication from light.
Side Effects of Wegovy
These include common gastrointestinal responses as well as rare, more severe physiological reactions.
Common Side Effects:
- Nausea and vomiting
- Diarrhea or constipation
- Abdominal pain and bloating
- Fatigue or headache
Serious Side Effects:
- Pancreatitis: Severe, persistent pain in the abdomen.
- Gallbladder problems: Including gallstones or inflammation.
- Kidney impairment: Changes in urination or swelling.
- Severe Allergic Reactions: Rash, swelling, or difficulty breathing.
Important Safety Information About Wegovy
Health Canada provides specific guidelines regarding family history and serious organ-related precautions.
Health Canada has issued warnings that Wegovy® should not be used by individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also monitored for its impact on the pancreas and gallbladder. Always disclose your full medical history to your doctor before starting this therapy.
Drug Interactions
Certain other medications and substances may influence how the body processes this specific therapy.
Because Wegovy® slows down the digestion process, it may affect how well the body absorbs oral medications taken at the same time. Potential interactions include:
- Insulin or Sulfonylureas: May increase the risk of low blood sugar.
- Other GLP-1 products: Should not be used in combination with Wegovy®.
- Herbal supplements: May interact with metabolic regulation.
Brands & DIN Number of Wegovy
Brand Names
- Ozempic®
- Mounjaro®
- Saxenda®
- Rybelsus®
DIN (Drug Identification Numbers)
02521997
Key Takeaways
- 1Wegovy® contains the active ingredient semaglutide.
- 2It is administered via a once-weekly subcutaneous injection.
- 3The drug belongs to the GLP-1 receptor agonist class.
- 4Requires strict temperature-controlled storage (2°C to 8°C).
- 5Mandatory prescription status in all Canadian provinces.